Clinical trials: Heart Failure With Preserved Ejection Fraction (HFPEF)
Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF
This is a Phase 2 dose-finding study in adult participants with symptomatic HFpEF.
- Trial name
- AMBER-HFpEF (NCT06793371)
- Testing
- CK-4021586 (150 mg, 300 mg, 450 mg, and 600 mg)
- Where
- 26 sites in United States
- Volunteers
- 60 people
- Sponsor
- Cytokinetics
Diastolic Heart Failure
Ranolazine in Diastolic Heart Failure
Patients with CAD and clinical symptoms of heart failure or patients with suspected heart failure with preserved ejection fraction (HFpEF) will be enrolled.
- Trial name
- RALI-DHF (NCT01163734)
- Testing
- Ranolazine
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Gilead Sciences
Heart Failure With Normal Ejection Fraction
Interleukin-1 Blockade in HF With Preserved EF
Heart Failure with Preserved Ejection Fraction (HFpEF) is a common form of heart failure Standard treatment for heart failure, show less than ideal results in HFpEF Evidence of systemic inflammation is common in all forms of…
- Trial name
- D-HART2 (NCT02173548)
- Testing
- Anakinra
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Virginia Commonwealth University
Heart Failure With Preserved Ejection Fraction
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- SP9In-HFpEF (NCT05312021)
- Testing
- IMR-687
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure With Preserved Ejection Fraction
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection Fraction
Beta blockers have been used to reduce the mortality and heart failure rehospitalization in heart failure with reduced ejection fraction (HFrEF) patients in addition to ACEI/ARB, MRA, ivabradine and ARNI.
- Trial name
- NCT03948685
- Testing
- Carvedilol SR
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Yonsei University
Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases
Staging Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is considered a systemic condition in which the prevalence of cardiovascular, metabolic, pulmonary and renal conditions determine the extent of cardiac involvement.
- Conditions
- Heart Failure With Preserved Ejection Fraction, Cardiovascular Diseases, Heart Failure
- Trial name
- StageHFpEF (NCT06931015)
- Testing
- No interventions
- Where
- Russia
- Volunteers
- 700 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Healthy Volunteers
Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects
This is a randomized, single-blind, placebo-controlled study conducted on healthy male subjects at a single study center to assess the safety, tolerability and the pharmacokinetics of AZD9977 following multiple-ascending oral…
- Trial name
- NCT03435276
- Testing
- AZD9977
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Failure
NoYA RAISE Trial II (Radiofrequency Ablation-Based Interatrial Shunt for Heart Failure)
A Prospective, Multiple Center, and Objective Performance Criteria Study to Evaluate the NoYA™ Radiofrequency Interatrial Shunt System manufactured by NoYA Medtech (Hangzhou) Co., Ltd.
- Trial name
- NCT05375110
- Testing
- NoYA™ Radiofrequency Interatrial Shunt System
- Where
- 31 sites in China
- Volunteers
- 120 people
- Sponsor
- Hangzhou NOYA MedTech Co. Ltm.